BioCT welcomes new member AlloMek
AlloMek Therapeutics is a privately held company focused on developing macrocycles for treating rare diseases. AlloMek’s most advance candidate, CIP-137401, is an IND ready molecule...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
AlloMek Therapeutics is a privately held company focused on developing macrocycles for treating rare diseases. AlloMek’s most advance candidate, CIP-137401, is an IND ready molecule...
Two University of Connecticut Health researchers will investigate the regulators of a cell type that plays a critical role in metabolic diseases associated with obesity....
Azitra reports that the FDA has granted Rare Pediatric Disease Designation to ATR-12 for the treatment of Netherton syndrome, a chronic genetic skin disease that can...
Giovanni Caforio, chairman and CEO of Bristol Myers Squibb, was recently interviewed in Fortune: “If there is any good news coming out of the coronavirus pandemic, it’s...
Biohaven reports the appointment of pharmaceutical industry leader Robert J. Hugin to its board of directors, effective immediately. Hugin previously was chairman and chief executive officer...
P2 Science has closed on a $3 million line of credit with Webster Bank. The company, which has a manufacturing plant in Naugatuck and research...
Last week at BIO Digital, Dr. Michelle McMurry-Heath, BIO’s President & CEO, moderated the panel “Leading Through Crisis: Speaking Up and Out on Equity, Diversity,...
Azitra has opened its new 12,000 square foot laboratory and office complex in Branford, CT. Previously operating out of three small labs located at the...
The Connecticut Legislature’s Regulations Review Committee has approved two new conditions to allow patients with chronic pain and an inherited disorder that affects the body’s...
Having a faulty gene linked to dementia doubles the risk of developing severe COVID-19, according to a large-scale study. Researchers at the University of Exeter...